Limitations, agreements, and source contact

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma · Source last updated 2026-08-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restriction Type

LTE60

restrictive Agreement

true

limitations And Caveats

description

Our trial has several limitations, including the short follow-up time. Secondary analyses and subgroup analyses that involved specified stratification factors were preplanned, but these analyses did not have adequate statistical power.

point Of Contact

email

hongli@fredhutch.org

organization

SWOG

phone

206-667-6077

title

Hongli Li

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice